Tuesday, January 10, 2017 11:15:27 AM
Roger Baylis-Duffield, Chief Executive Officer of Plandaí, commented, "This strategic moves allows us to separate the research component of our business into a separate, self-funding entity, freeing up Plandaí to focus on Phytofare® manufacture and sales. Plandaí SA will operate with distinct management concentrating on pharmaceutical applications and obtaining drug and structure-function claims. Where Plandaí produces and sells an ingredient to the nutraceutical industry, Plandaí SA will produce a finished product targeting a specific application, such as managing glucose levels in diabetics.
Plandaí SA will operate with distinct management concentrating on pharmaceutical applications and obtaining drug and structure-function claims.
LEWIS IS OUT! GONE! BYE BYE! I guess there is no point talking about Lewis anymore.
*** EVERY DAY IS A GOOD DAY FOR LEARN! *** GOD BLESS YOU! :)
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM